Kaiser Permanente has been named California’s Most Recommended Health Insuranc... Read More
ACHP Live Interview —
High-Cost Drugs: Challenges and Opportunities
Date: Monday, June 15
- Kavita Patel, M.D., Managing Director, Clinical Transformation, Brookings Institution Center for Health Policy (Moderator)
- Ceci Connolly, Managing Director, PwC’s Health Research Institute
- Leslie Fish, Vice President of Clinical Programs, Fallon Health
- Eileen Wood, Vice President of Clinical Integration and Chief Pharmacy Officer, Capital District Physicians’ Health Plan
The Alliance of Community Health Plans (ACHP) facilitated a conversation about high-cost drugs and the effect of these high prices on patients, insurers, providers and state and federal governments. The discussion focused on drug pricing trends; how new drugs are helping patients; strategies for ensuring patients have access to appropriate drugs; and emerging specialty drugs, such as the PCSK9 inhibitors for control of high cholesterol.
Included among the key takeaways from the conversation offered by the panelists:
- There is a need to use alternative financing models and think about the high-cost drug issue in the context of alternative payment models as care delivery continues to evolve. The separation of pharmaceuticals and the delivery of care needs to end.
- All sectors of health care, not just pharmacy, are being asked to deliver a high rate of service with fewer resources. As this trend continues, there is a need to begin pilot programs testing alternative financing models.
- Consumers and health care providers continue to be inundated with drugs introduced to the market as the priority for particular disease states. There is a need to weigh the risks and benefits of these drugs to other drugs and alternative treatments.
- High cost is not only an issue with specialty drugs; all drug prices are increasing.
- There is a need to unify value messaging around the drug cost issue and use organizations with which we are associated to disseminate the message to the public.